NCT00276458已完成3 期
A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 Mg
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 196
- 主要终点
- Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
研究概览
简要总结
The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately controlled on atorvastatin 20 mg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with LDL-C >100 mg/dL & on a stable dose of atorvastatin 20 mg
排除标准
- •Pregnant or lactating women or intending to become pregnant
- •Patient with sensitivity or intolerance to ezetimibe or atorvastatin
- •Patient with diabetes or coronary heart disease
结局指标
主要结局
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
时间窗: 6 weeks
\[(6 week value - baseline value)/baseline value\]\*100%.
次要结局
- Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6(6 Weeks)
- Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6(6 Weeks)
- Number of Participants Who Attained Target LDL-C <100 mg/dL at Week 6(6 weeks)
- Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6(6 weeks)
- Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6(6 Weeks)
- Percent Change From Baseline in Total-Cholesterol at Week 6(6 Weeks)
- Percent Change From Baseline in Apolipoprotein B at Week 6(6 Weeks)
- Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6(6 Weeks)
- Percent Change From Baseline in Triglycerides (TG) at Week 6(6 weeks)
- Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6(6 Weeks)
- Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6(6 Weeks)
研究者
相似试验
已完成
4 期
The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)HypercholesterolemiaCoronary DiseaseNCT00423579Organon and Co120
已完成
3 期
Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)Diabetes Mellitus, Type 2NCT00551876Organon and Co214
已完成
3 期
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)HypercholesterolemiaNCT00276484Organon and Co579
已完成
3 期
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)AtherosclerosisHypercholesterolemiaCoronary Artery DiseaseNCT00650689Organon and Co122
已完成
3 期
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)HypercholesterolemiaNCT01370603Organon and Co328